Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Study Summary

This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combination with darolutamide in subjects with mCRPC.

Conditions

mCRPC (Metastatic Castration-resistant Prostate Cancer)Genital Diseases, Male Urogenital Diseases, Male Prostatic Disease Prostatic Neoplasms, Castration-Resistant Prostate Cancer

Interventions / Drugs

Gedatolisib Darolutamide

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment54 participants

Primary Completion—

Lead SponsorCelcuity Inc

Data Retrieved2026-04-11 04:09:11.213923+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.